2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes …

F Cosentino, PJ Grant, V Aboyans… - European heart …, 2020 - academic.oup.com
Health professionals are encouraged to take the Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary …

J Knuuti, W Wijns, A Saraste, D Capodanno… - European heart …, 2020 - academic.oup.com
Health professionals are encouraged to take the ESC Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …

Treatment of type 2 diabetes: challenges, hopes, and anticipated successes

MA Nauck, J Wefers, JJ Meier - The lancet Diabetes & endocrinology, 2021 - thelancet.com
Despite the successful development of new therapies for the treatment of type 2 diabetes,
such as glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose …

Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association

SV Arnold, DL Bhatt, GW Barsness, AL Beatty… - Circulation, 2020 - ahajournals.org
Although cardiologists have long treated patients with coronary artery disease (CAD) and
concomitant type 2 diabetes mellitus (T2DM), T2DM has traditionally been considered just a …

2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European …

Task Force Members, G Montalescot… - European heart …, 2013 - academic.oup.com
Surveys and registries are needed to verify that real-life daily practice is in kee** with what
is recommended in the guidelines, thus completing the loop between clinical research …

Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a …

BS Wiggins, JJ Saseen, RL Page, BN Reed, K Sneed… - Circulation, 2016 - ahajournals.org
A n D GUID eLIneS affordability may often dictate which medications may be prescribed.
Patients who have exhausted prescription drug coverage or who are uninsured may require …

Coronary microvascular dysfunction: clinical considerations and noninvasive diagnosis

TH Schindler, V Dilsizian - Cardiovascular imaging, 2020 - jacc.org
Chest pain in patients without obstructive coronary artery disease has been realized as a
frequent problem encountered in clinical practice. Invasive flow investigations have …

[HTML][HTML] A'diamond'approach to personalized treatment of angina

R Ferrari, PG Camici, F Crea, N Danchin… - Nature Reviews …, 2018 - nature.com
In clinical guidelines, drugs for symptomatic angina are classified as being first choice (β-
blockers, calcium-channel blockers, short-acting nitrates) or second choice (ivabradine …

Natural history of patients with ischemia and no obstructive coronary artery disease: the CIAO-ISCHEMIA study

HR Reynolds, MH Picard, JA Spertus, J Peteiro… - Circulation, 2021 - ahajournals.org
Background: Ischemia with no obstructive coronary artery disease (INOCA) is common and
has an adverse prognosis. We set out to describe the natural history of symptoms and …

Development and validation of a short version of the Seattle angina questionnaire

PS Chan, PG Jones, SA Arnold… - … Quality and Outcomes, 2014 - ahajournals.org
Background—Clinical trials and national performance measures increasingly mandate
reporting patients' perspectives of their health status: their symptoms, function, and quality of …